ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
June 02, 2021 16:55 ET | ORIC Pharmaceuticals
Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations ...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 25, 2021 08:00 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 06, 2021 16:05 ET | ORIC Pharmaceuticals
Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06,...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
April 28, 2021 16:05 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 23, 2021 16:05 ET | ORIC Pharmaceuticals
Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cash Equivalents and Investments of $293.6 million...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 10, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
March 02, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
February 03, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...